6534 — CH Biotech R&D Co Cashflow Statement
0.000.00%
- TWD8.23bn
- TWD8.23bn
- TWD1.51bn
- 72
- 43
- 33
- 47
Annual cashflow statement for CH Biotech R&D Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 242 | 127 | 360 | 566 | 579 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 26.1 | 22.3 | 13.3 | 13.3 | 4.92 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -51 | -14.9 | -205 | -19.8 | -90.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 305 | 233 | 264 | 699 | 659 |
Capital Expenditures | -140 | -108 | -44.9 | -108 | -107 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.581 | -0.167 | 0.12 | -9.64 | -36.3 |
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -139 | -109 | -44.8 | -117 | -143 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -232 | -81.7 | -222 | -375 | -107 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -66.3 | 42 | -3 | 209 | 410 |